Dietary pyrroloquinoline quinone supplementation improves productive performance, immunity, and intestinal health in late-phase Jingfen No. 6 laying hens Authors: Xuehuai Shen, Wei Liu, Xisongliang Wang, Ruihong Zhao, Lei Yin, Dongdong Yin, Yin Dai, Hongyan Hou, Jieru Wang, Xiaomiao Hu, Xiaocheng Pan, Yongjie Liu, Kai Zhan Published: 2026 ABSTRACT This study evaluated the effects of dietary pyrroloquinoline quinone (PQQ) on the productive performance, biochemical parameters, immune function, and intestinal health of laying hens during the late laying period. A total of 360 Jingfen No. 6 laying hens, aged 48 weeks, were randomly assigned to 5 dietary treatments (0, 0.5, 1.0, 2.0, and 4.0 mg/kg PQQ), with 6 replicates per treatment and 12 birds per replicate. Egg production performance, serum antibody titers, blood biochemical and immune indices, intestinal morphology, tight junction protein expression, and cecal microbiota and metabolite profiles were determined. The results showed that dietary supplementation with 0.5 and 1.0 mg/kg PQQ increased average daily egg mass and egg production rate (P < 0.01) and decreased the feed-to-egg ratio (P < 0.01). PQQ reduced serum malondialdehyde (MDA) and lactate dehydrogenase (LDH) levels (P < 0.05), alongside a significant increase in catalase (CAT) activity (P < 0.05). Antibody titers against H5, H7, and NDV were elevated in all PQQ-treated groups, with significant differences for H5 and NDV antibodies at 0.5 and 1.0 mg/kg groups (P < 0.05) and H7 antibodies in the 0.5 mg/kg group (P < 0.05). PQQ supplementation increased intestinal mucosal secretory immunoglobulin A (sIgA) content (P < 0.05), decreased serum interleukin-6 (IL-6) levels across all treatment doses (P < 0.01), and reduced IL-10 concentrations at 1.0 mg/kg (P < 0.05). Morphological analysis revealed that PQQ significantly increased jejunal villus height and the villus height-to-crypt depth ratio (P < 0.05 and P < 0.01), while upregulating mRNA expression of the tight junction proteins ZO-1 and Occludin (P < 0.05). PQQ significantly enhanced the relative abundance of beneficial bacterial genera including Prevotellaceae_Ga6A1_group, Lactobacillus, and Faecalibacterium. Metabolomic analysis revealed that PQQ predominantly upregulated intestinal organic acids including 6-(Pyridin-3-YL)hexanoic acid, DL-Valine-4-antipyrineamide, Eicosadienic acid, 2-methyl-hexadecanoic acid, and Penicilloic acid, while downregulating lipid metabolites including Triglycerides (TG), Phosphatidylglycerol (PG), and Phosphatidylcholine (PC). In conclusion, 0.5 to 1.0 mg/kg PQQ is optimal for enhancing productivity and antibody production in the late-phase laying hens through minimized oxidative damage, attenuated inflammation, and restructured intestinal microbiota and metabolic profiles. Introduction The laying hen industry is a critical component of global animal agriculture, providing a high-quality, economical source of animal protein for human consumption. However, modern intensive production systems present significant physiological challenges for aging hens. As laying hens transition into the late production phase (typically beyond 45 weeks of age), they undergo significant physiological changes that compromise productivity and health. During this period, ovarian follicular recruitment declines and the regression of existing follicles accelerates, leading to a progressive decrease in egg production rate and egg quality (Attia et al., 2020). Concurrently, aging hens experience deteriorating antioxidant capacity characterized by reduced activities of superoxide dismutase, catalase, and glutathione peroxidase, coupled with elevated lipid peroxidation products in serum and tissues (Bai et al., 2023). This oxidative imbalance not only contributes to cellular senescence but also compromises immune competence, as evidenced by diminished antibody responses to vaccination and altered cytokine profiles (Lai et al., 2025; Liu et al., 2023). Furthermore, age-related changes in intestinal morphology, including reduced villus height, increased crypt depth, and downregulated expression of tight junction proteins, impair nutrient absorption efficiency and barrier integrity (Hu et al., 2024). The intestinal microbiota composition also shifts during late lay, with reduced diversity that may negatively impact host metabolism and immune homeostasis (Khan et al., 2020; Su et al., 2026). These multifaceted age-related changes create a physiological environment where targeted nutritional interventions can be particularly effective in mitigating performance decline and improving overall health status. Pyrroloquinoline quinone (PQQ) is an aromatic tricyclic ortho-quinone compound ubiquitously found in microorganisms, plants, and animals. Discovered in the 1960s, PQQ has been extensively characterized as a novel organic cofactor with diverse biological functions (Xue et al., 2026). Research has demonstrated that PQQ possesses multiple biological activities, including promoting mitochondrial biogenesis, enhancing energy metabolism, exhibiting antioxidant properties, stimulating growth and reproduction, modulating immune responses, and providing neuroprotection (Davide et al., 2024; Jonscher et al., 2021). As an efficient electron transporter, PQQ exhibits potent antioxidant activity; its reduced form demonstrates superior free radical scavenging capacity compared to vitamin C (Akagawa et al., 2016). Given its health benefits, PQQ has been approved as a dietary supplement in the United States and the European Union (Davide et al., 2024; Turck et al., 2017). In the field of animal nutrition and health regulation, research on PQQ application has achieved incremental progress. In poultry production, dietary supplementation with an appropriate level of PQQ disodium salt has been shown to improve growth performance, carcass yield, and antioxidant capacity in broilers (Samuel et al., 2015; Wang et al., 2015). In laying hens, PQQ enhances egg quality by increasing albumen height and Haugh units while boosting systemic antioxidant function (Shao et al., 2023; Wang et al., 2016). Regarding immune modulation, dietary PQQ has been reported to significantly reduce the levels of pro-inflammatory cytokines in the jejunal tissue of weaned piglets (Yin et al., 2019) and to attenuate the inflammatory response induced by lipopolysaccharide (LPS) challenge in broilers, decreasing serum pro-inflammatory cytokine levels (Huang et al., 2020; Zheng et al., 2020). PQQ also appears to modulate the composition of the intestinal microbiota. Studies in weaned piglets have found that dietary PQQ supplementation can decrease the relative abundance of potentially harmful bacteria in the cecum while increasing that of beneficial bacteria, concomitantly promoting the production of short-chain fatty acids (Huang et al., 2020; Yin et al., 2019). Based on these observations, we hypothesized that dietary PQQ supplementation might enhance production performance and health status in late-laying hens through multiple mechanisms, including bolstering antioxidant capacity, modulating immune function, preserving intestinal structural integrity, and reshaping the gut microbiota-metabolome axis. Although previous studies have documented the effects of PQQ on growth performance, antioxidant capacity, or liver health in poultry, these investigations typically examined isolated endpoints. Consequently, the specific mechanisms through which PQQ modulates the intestinal microbiota to influence host nutrient utilization, barrier integrity, and systemic immunity remain insufficiently elucidated. The present study extends prior work by employing an integrative multi-omics framework that links PQQ-induced alterations in cecal microbial community structure and metabolite profiles to measurable improvements in intestinal morphology, immune function, and production performance in late-laying Jingfen No. 6 hens. These findings furnish a more comprehensive mechanistic rationale for PQQ supplementation and offer practical guidance for its application in aging laying flocks. Materials and methods Experimental animals and housing Jingfen No. 6 is a commercially popular brown-egg laying hen strain in China, developed through selective breeding for high egg production efficiency, feed conversion ratio, and disease resistance (Li et al., 2023; Lv et al., 2022). This breed is widely used in Chinese poultry production systems and has been extensively employed in nutritional intervention studies. A total of 360 healthy Jingfen No. 6 laying hens, aged 48 weeks, were randomly allocated to 5 experimental groups, with 6 replicates per group and 12 hens per replicate. The hens were housed at the Experimental Animal Facility of the Institute of Animal Husbandry and Veterinary Medicine, Anhui Academy of Agricultural Sciences. Following a 7-day pre-experimental period, it was confirmed that all groups exhibited comparable health status, productive performance, and baseline antibody titers against avian influenza and Newcastle disease virus prior to the start of the experiment. Experimental design and diets Laying hens were randomly assigned to one of five experimental groups: a control group and four treatment groups receiving graded levels of PQQ. Hens in the control group were fed a basal diet (as shown in Table 1), while those in the treatment groups were fed the basal diet supplemented with PQQ at concentrations of 0.5, 1, 2, and 4 mg/kg diet. All hens were managed under identical conditions, including feeding and watering regimens. The feeding trial lasted for 30 days, during which all experimental diets were provided ad libitum throughout the entire experimental period. Birds were manually fed twice daily, at 08:00 h and 14:00 h. All experimental procedures involving animal care, management, vaccination, and euthanasia were conducted in accordance with the institutional animal care guidelines of Anhui Academy of Agricultural Sciences and strictly adhered to the requirements specified in the Laboratory Animal Welfare and Ethics Review Guidelines (National Standard of the People's Republic of China, GB/T 35892-2018).Table 1Composition and nutrient levels of the basal diet.IngredientsContent (%)NutrientsNutritional level(2)Corn62.8Crude protein (%)15.6Soybean meal23.2Metabolizable energy (kcal/kg)2670Limestone8.0Lysine (%)0.82Oil1.0Methionine (%)0.40Premix(1)5.0Calcium (%)3.75Total100.0Total phosphorus (%)0.50Notes: (1) The premix provided the following per kilogram of diet: VA 54,000 IU, VD₃ 28,000 IU, VE 250 IU, VB₁ 32 mg, VB₂ 80 mg, VB₆ 50 mg, VB₁₂ 0.10 mg, niacin 300 mg, pantothenic acid 400 mg, folic acid 12 mg, biotin 4 mg, choline 1.2 g, Cu 100 mg, Fe 1,000 mg, Mn 800 mg, Zn 800 mg, Se 2.5 mg, methionine 0.8%; (2). Nutrient levels were calculated values. (3) The dietary formulation was prepared in accordance with the nutrient requirements and feeding guidelines for laying hens aged 45 to 60 wk, as stipulated in the Feeding Standard of Poultry (NY/T 33-2004, Ministry of Agriculture and Rural Affairs of China) and the Management Manual for Jingfen No. 6 laying hens. Table 1Composition and nutrient levels of the basal diet.IngredientsContent (%)NutrientsNutritional level(2)Corn62.8Crude protein (%)15.6Soybean meal23.2Metabolizable energy (kcal/kg)2670Limestone8.0Lysine (%)0.82Oil1.0Methionine (%)0.40Premix(1)5.0Calcium (%)3.75Total100.0Total phosphorus (%)0.50Notes: (1) The premix provided the following per kilogram of diet: VA 54,000 IU, VD₃ 28,000 IU, VE 250 IU, VB₁ 32 mg, VB₂ 80 mg, VB₆ 50 mg, VB₁₂ 0.10 mg, niacin 300 mg, pantothenic acid 400 mg, folic acid 12 mg, biotin 4 mg, choline 1.2 g, Cu 100 mg, Fe 1,000 mg, Mn 800 mg, Zn 800 mg, Se 2.5 mg, methionine 0.8%; (2). Nutrient levels were calculated values. (3) The dietary formulation was prepared in accordance with the nutrient requirements and feeding guidelines for laying hens aged 45 to 60 wk, as stipulated in the Feeding Standard of Poultry (NY/T 33-2004, Ministry of Agriculture and Rural Affairs of China) and the Management Manual for Jingfen No. 6 laying hens. Composition and nutrient levels of the basal diet. Notes: (1) The premix provided the following per kilogram of diet: VA 54,000 IU, VD₃ 28,000 IU, VE 250 IU, VB₁ 32 mg, VB₂ 80 mg, VB₆ 50 mg, VB₁₂ 0.10 mg, niacin 300 mg, pantothenic acid 400 mg, folic acid 12 mg, biotin 4 mg, choline 1.2 g, Cu 100 mg, Fe 1,000 mg, Mn 800 mg, Zn 800 mg, Se 2.5 mg, methionine 0.8%; (2). Nutrient levels were calculated values. (3) The dietary formulation was prepared in accordance with the nutrient requirements and feeding guidelines for laying hens aged 45 to 60 wk, as stipulated in the Feeding Standard of Poultry (NY/T 33-2004, Ministry of Agriculture and Rural Affairs of China) and the Management Manual for Jingfen No. 6 laying hens. Productive performance determination During the experimental period, the number of eggs laid and total egg mass were recorded for each group. Residual feed in the troughs was collected and weighed daily between 07:30 h and 08:00 h using an electronic balance (0.01 g precision), and the daily feed residue for each replicate was recorded. Based on the recorded data, feed intake, egg production rate, and feed-to-egg ratio were calculated for each experimental group. Immunization and antibody detection On day 3 of the experiment, hens received booster vaccinations with an inactivated trivalent avian influenza vaccine (H5N6 H5-Re13 strain + H5N8 H5-Re14 strain + H7N9 H7-Re4 strain, Harbin Weike Biotechnology Co., Ltd., Harbin, China) administered intramuscularly in the pectoral muscle at 0.5 mL per bird, and a combined Newcastle disease virus (NDV) and infectious bronchitis virus live vaccine (La Sota strain + H120 strain, Qingdao Yebio Bioengineering Co., Ltd., Qingdao, China) delivered via drinking water at 1.5 × the standard dose. Blood samples were collected from the wing vein prior to vaccination and at 30 d post-vaccination from 2 birds per replicate cage (n = 12 per treatment). Serum was harvested by centrifugation at 3, 000 × g for 10 min at 4°C and stored at -20°C until analysis. Serum antibody titers against avian influenza virus H5 and H7 subtypes were determined by hemagglutination inhibition assay in accordance with the national standard of China (GB/T 18936-2025, Diagnostic Techniques for Avian Influenza). Newcastle disease virus antibody titers were measured in accordance with the national standard of China (GB/T 16550-2020, Diagnostic Techniques for Newcastle Disease). Egg quality assessment On day 30, 30 eggs per treatment (5 eggs per replicate cage) were randomly collected for quality evaluation. Egg weight, length, and width were recorded. The egg shape index was calculated as egg length to egg width. Egg weight was recorded, and eggs were subsequently broken to separate yolk and albumen. Yolk weight was measured. Shell strength was determined using an eggshell force gauge (EFG-0503, Robotmation Co., Ltd., Tokyo, Japan). Egg weight, yolk color, albumen height, and Haugh unit were measured using a digital egg tester (EA-01, ORKA Food Technology Ltd., Ramat Hasharon, Israel). Shell color was assessed with a colorimeter (QCR-SC, TSS Ltd., York, UK). After manual removal of the shell membranes, eggshell thickness was measured at 3 equatorial points (top, middle, and bottom) using a digital micrometer (293-100MDH, Mitutoyo Corporation, Kawasaki, Japan) and averaged. Serum biochemical index determination On day 30 of PQQ supplementation, 18 hens were randomly selected from each group (n=3 per replicate). Following a 12-h fasting period, blood samples were collected from the wing vein, and serum was separated for biochemical analysis. The serum levels of malondialdehyde (MDA), lactate dehydrogenase (LDH), superoxide dismutase (SOD), catalase (CAT), and total antioxidant capacity (T-AOC) were measured. All biochemical parameters were determined using commercial kits purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China), and the assays were performed in strict accordance with the manufacturer's instructions. Immune parameter determination Serum concentrations of IL-2, IL-6, IL-10, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), immunoglobulin G (IgG), and IgA were measured by ELISA. Besides, secretory IgA (sIgA) concentration in the jejunal mucosa was determined. All ELISA kits were purchased from Wuhan Genemei Technology Co., Ltd. (Wuhan, China), and procedures were performed according to the manufacturer's instructions. Intestinal histomorphology Based on the productive performance, antibody titers, and serum biochemistry and immunological factors results, the 1.0 mg/kg PQQ supplementation group, which demonstrated the most comprehensive improvements in laying rate, feed conversion ratio, antibody titers, and serum indicators, was selected for subsequent intestinal morphology, microbiome, and metabolomics analyses. This dose-selection approach, while resource-efficient, represents a limitation of the study as it precludes dose-response characterization of these parameters. At the end of the experiment, 6 hens per treatment from the control and 1 mg/kg PQQ groups (1 per replicate) were euthanized by cervical dislocation. Mid-jejunum segments (approximately 2 cm) were collected, flushed with ice-cold phosphate-buffered saline, and fixed in 10% neutral buffered formalin for 24 h. Tissues were embedded in paraffin, sectioned at 4 μm (RM2135, Leica Microsystems, Wetzlar, Germany), and stained with hematoxylin and eosin (BASO Biotechnology Co., Ltd., Zhuhai, China) following established procedures (Shen et al., 2022). Sections were examined under a light microscope (Eclipse 80i, Nikon Corporation, Tokyo, Japan) at 50 × magnification. Villus height (from the tip to the crypt-villus junction) and crypt depth (from the crypt-villus junction to the base) were measured using CaseViewer software (3DHISTECH, Budapest, Hungary) by a blinded observer. Immunofluorescence staining Jejunal tissue sections were deparaffinized, rehydrated, and washed with PBST (PBS containing 0.1% Tween-20). The sections were then treated with 3% hydrogen peroxide to block endogenous peroxidase activity, followed by 10% bovine serum albumin (BSA) blocking at room temperature for 2 h. Rabbit polyclonal antibody against ZO-1 was diluted 1:500 in PBST containing 1% BSA and incubated with the sections at 37°C for 1 h. After three washes with PBST, the sections were incubated with goat anti-rabbit fluorescently labeled secondary antibody in the dark for 1 h. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI), and the sections were examined under a fluorescence microscope. Quantitative real-time PCR Total RNA was extracted from jejunal tissue samples using TRIzol reagent (Takara, Beijing, China). A total of 2 μg of RNA was reverse transcribed into complementary DNA (cDNA) using PrimeScript™ RT Master Mix (Takara, Beijing, China) according to the manufacturer's protocol. Real-time PCR was performed using SYBR Green PCR Master Mix in a 20 μL reaction system. The primer sequences for zonula occludens-1 (ZO-1), Occludin, Claudin-1, and the internal reference gene β-actin are listed in Table 2. All samples were analyzed in triplicate using the ABI 7500 real-time PCR System (Applied Biosystems, USA). The relative mRNA expression levels of target genes were calculated using the 2−△△Ct method, with β-actin serving as the internal control. Primers were synthesized by General Biotechnology Co., Ltd. (Hefei, China).Table 2Primers used for real-time PCR analysis.Gene namePrimer sequence (5′to 3′)Amplification efficiency (%)Accession numberZO-1CAGTCTGTGCGAAGTAGAGT103.0XM_046925209.1GAGGTTTGACAACTGACGTGClaudin-1CGGAGTGAAACATCCTACCC94.8NM_001013611.2GGCATTGTAGTGTCCTCTCCOccludinACAAGCTCTTCCACATCAAG99.1NM_205128.1GGATGTGATTGAGTGTGTTTβ-actinACGTCGCACTGGATTTCGAG98.5NM_205518.2TGTCAGCAATGCCAGGGTAC Table 2Primers used for real-time PCR analysis.Gene namePrimer sequence (5′to 3′)Amplification efficiency (%)Accession numberZO-1CAGTCTGTGCGAAGTAGAGT103.0XM_046925209.1GAGGTTTGACAACTGACGTGClaudin-1CGGAGTGAAACATCCTACCC94.8NM_001013611.2GGCATTGTAGTGTCCTCTCCOccludinACAAGCTCTTCCACATCAAG99.1NM_205128.1GGATGTGATTGAGTGTGTTTβ-actinACGTCGCACTGGATTTCGAG98.5NM_205518.2TGTCAGCAATGCCAGGGTAC Primers used for real-time PCR analysis. Analysis of intestinal microbiota and major metabolites At the end of the experiment, cecal contents were collected from hens in the control group and the 1.0 mg/kg PQQ supplementation group and stored at -80°C. Total DNA was extracted from the samples using the cetyltrimethylammonium bromide (CTAB) method according to the manufacturer's instructions (Thermo Fisher Scientific) and stored at -80°C for subsequent analysis of the intestinal microbiota. Major metabolites in the intestinal contents were identified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) following standard procedures, including sample pretreatment, metabolite extraction, full-scan LC-MS/MS acquisition, data preprocessing, and statistical analysis. Differential metabolites were identified based on Student's t-test (P < 0.05) combined with fold change (FC ≥ 4.0 or FC ≤ 0.25). The analyses of intestinal microbiota, major metabolomics, and bioinformatics were conducted by Shanghai Ouyi Biomedical Technology Co., Ltd. (Shanghai, China). Statistical analysis Data were initially processed using Microsoft Excel (Microsoft Corp., Redmond, WA) and analyzed by one-way ANOVA using SPSS 16.0 (IBM Corp., Armonk, NY). Means were compared using Duncan's multiple range test when significant differences were detected. Results were presented as mean ± standard error (SEM). Differences were considered statistically significant at P < 0.05 and extremely significant at P < 0.01. All graphs were generated using GraphPad (version 8; GraphPad Software, CA, USA). Results Effects of PQQ supplementation on productive performance of laying hens The productive performance parameters of hens in each experimental group are presented in Table 3. Compared with the control group, hens receiving 1.0 mg/kg PQQ supplementation exhibited a significant increase in average daily feed intake (ADFI) (P < 0.05), whereas those in the 4.0 mg/kg group showed a significant decrease (P < 0.05). Both average daily egg mass and egg production rate were significantly increased in the 0.5 mg/kg and 1.0 mg/kg PQQ supplementation groups (P < 0.01). Analysis of the feed-to-egg ratio revealed that all groups supplemented with PQQ exhibited lower ratios than the control group, which maintained an average ratio of 2.29. Specifically, the 0.5 mg/kg and 1.0 mg/kg PQQ treatment groups yielded average feed-to-egg ratios of 2.20 and 2.21, respectively. Both values were significantly lower than those of the control group (P < 0.01).Table 3Effects of PQQ supplementation on productive performance of laying hens during the late laying period.ParametersGroupsP-valuesControl0.5 mg/kg1.0 mg/kg2.0 mg/kg4.0mg/KgAverage feed intake (g/hen/day)114.15±1.71b113.98±1.58b115.30±1.28a*114.84±1.53ab113.01±3.02c*<0.001Average egg mass (g/hen/day)50.15±3.56b51.82±1.85a⁎⁎52.17±1.92a⁎⁎50.59±1.25b50.64±1.83b0.001Average egg production rate (%)86.74±0.88b91.65±0.68a⁎⁎91.03±0.61a⁎⁎88.39±0.47b88.38±0.59b<0.001Feed-to-egg ratio2.28±0.03b2.20±0.01a⁎⁎2.21±0.02a⁎⁎2.27±0.01b2.24±0.02ab0.005Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group.⁎P < 0.05.⁎⁎P < 0.01. Table 3Effects of PQQ supplementation on productive performance of laying hens during the late laying period.ParametersGroupsP-valuesControl0.5 mg/kg1.0 mg/kg2.0 mg/kg4.0mg/KgAverage feed intake (g/hen/day)114.15±1.71b113.98±1.58b115.30±1.28a*114.84±1.53ab113.01±3.02c*<0.001Average egg mass (g/hen/day)50.15±3.56b51.82±1.85a⁎⁎52.17±1.92a⁎⁎50.59±1.25b50.64±1.83b0.001Average egg production rate (%)86.74±0.88b91.65±0.68a⁎⁎91.03±0.61a⁎⁎88.39±0.47b88.38±0.59b<0.001Feed-to-egg ratio2.28±0.03b2.20±0.01a⁎⁎2.21±0.02a⁎⁎2.27±0.01b2.24±0.02ab0.005Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group.⁎P < 0.05.⁎⁎P < 0.01. Effects of PQQ supplementation on productive performance of laying hens during the late laying period. Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group. P < 0.05. P < 0.01. Effects of PQQ supplementation on avian influenza and newcastle disease antibody titers in laying hens The effects of dietary PQQ supplementation on immune antibody titers in late-laying Jingfen No. 6 hens are presented in Table 4. During the pre-experimental period, no significant differences were observed in serum H5, H7, or NDV antibody titers among the experimental groups. On day 30, all PQQ-supplemented groups exhibited higher antibody titers against H5, H7, and NDV compared to the control group. Specifically, hens treated with 0.5 mg/kg and 1.0 mg/kg PQQ showed significantly higher H5 antibody titers than the control group (P < 0.05 and P < 0.01, respectively). The H7 antibody titer was significantly higher in the 0.5 mg/kg PQQ group than in the control group (P < 0.01). Furthermore, NDV antibody titers were significantly elevated in both the 0.5 mg/kg and 1.0 mg/kg PQQ supplementation groups compared with the control group (P < 0.05 and P < 0.01, respectively).Table 4Antibody titers of experimental hens fed diets supplemented with PQQ (Mean ± SE).Experimental periodAntibodyGroupsP-valuesControl0.5 mg/kg1.0 mg/kg2.0 mg/kg4.0mg/KgPre-experimentalH 55.07±0.195.05±0.174.63±0.164.75±0.144.82±0.190.305H75.32±0.185.42±0.185.27±0.155.45±0.185.57±0.160.750ND7.24±0.257.39±0.197.18±0.237.20±0.187.37±0.220.92730 d post-treatmentH 58.18±0.17a8.87±0.17b*8.83±0.20b⁎⁎8.32±0.19a8.47±0.16a0.030H78.54±0.20a9.22±0.14b⁎⁎8.96±0.16a8.88±0.15a8.87±0.17a0.090ND7.59±0.32a8.74±0.19b⁎⁎8.35±0.19b*7.92±0.20a7.96±0.22a0.007Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group.⁎P < 0.05.⁎⁎P < 0.01. Table 4Antibody titers of experimental hens fed diets supplemented with PQQ (Mean ± SE).Experimental periodAntibodyGroupsP-valuesControl0.5 mg/kg1.0 mg/kg2.0 mg/kg4.0mg/KgPre-experimentalH 55.07±0.195.05±0.174.63±0.164.75±0.144.82±0.190.305H75.32±0.185.42±0.185.27±0.155.45±0.185.57±0.160.750ND7.24±0.257.39±0.197.18±0.237.20±0.187.37±0.220.92730 d post-treatmentH 58.18±0.17a8.87±0.17b*8.83±0.20b⁎⁎8.32±0.19a8.47±0.16a0.030H78.54±0.20a9.22±0.14b⁎⁎8.96±0.16a8.88±0.15a8.87±0.17a0.090ND7.59±0.32a8.74±0.19b⁎⁎8.35±0.19b*7.92±0.20a7.96±0.22a0.007Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group.⁎P < 0.05.⁎⁎P < 0.01. Antibody titers of experimental hens fed diets supplemented with PQQ (Mean ± SE). Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group. P < 0.05. P < 0.01. Effects of PQQ supplementation on egg quality The effects of dietary PQQ supplementation on egg quality parameters in late-laying hens during the late laying period are presented in Table 5. Compared with the control group, dietary supplementation with different concentrations of PQQ yielded no significant effects on egg shape index, egg weight, eggshell specific gravity, or yolk specific gravity. Eggshell strength was generally higher in PQQ-supplemented groups than in the control group, with a significant increase observed in the 4.0 mg/kg group (P < 0.05). In contrast, eggshell thickness was generally lower in PQQ-supplemented groups compared to the control, and the reduction was significant in the 2.0 mg/kg group (P < 0.05). Albumen height and Haugh unit values were slightly lower in all PQQ-supplemented groups than in the control group, although the differences did not reach statistical significance. Yolk color scores were marginally higher in PQQ-supplemented groups compared to the control, but these differences did not reach statistical significance (P > 0.05).Table 5Effects of PQQ supplementation on egg quality parameters of laying hens.ParametersGroupsP-valuesControl0.5 mg/kg1.0 mg/kg2.0 mg/kg4.0mg/KgEgg weight (g)57.38±0.8657.44±0.8557.08±0.7657.47±0.7257.48±0.820.996Egg shape index1.31±0.011.32±0.011.32±0.011.33±0.011.31±0.010.628Eggshell specific gravity (%)14.42±0.2514.31±0.3614.42±0.2314.29±0.3414.01±0.250.866Yolk specific gravity (%)27.87±0.3027.81±0.4127.92±0.3127.98±0.3027.48±0.330.853Eggshell strength (kg/cm²)3.69±0.15a3.87±0.12a4.05±0.09b*3.70±0.17a4.17±0.11b*0.041Eggshell thickness (mm)0.355±0.005a0.346±0.004a0.343±0.003a0.340±0.005 b*0.348±0.004a0.049Eggshell color (HG)54.18±1.0354.32±0.9952.91±0.8156.18±0.9454.18±0.590.142Albumen height (mm)5.86±0.185.37±0.165.55±0.255.68±0.215.72±0.270.572Haugh unit76.14±1.4472.29±1.4672.75±2.5974.26±1.9673.70±2.960.733Yolk color6.72±0.187.14±0.186.72±0.137.06±0.176.81±0.180.239Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group, ⁎⁎P < 0.01.⁎P < 0.05. Table 5Effects of PQQ supplementation on egg quality parameters of laying hens.ParametersGroupsP-valuesControl0.5 mg/kg1.0 mg/kg2.0 mg/kg4.0mg/KgEgg weight (g)57.38±0.8657.44±0.8557.08±0.7657.47±0.7257.48±0.820.996Egg shape index1.31±0.011.32±0.011.32±0.011.33±0.011.31±0.010.628Eggshell specific gravity (%)14.42±0.2514.31±0.3614.42±0.2314.29±0.3414.01±0.250.866Yolk specific gravity (%)27.87±0.3027.81±0.4127.92±0.3127.98±0.3027.48±0.330.853Eggshell strength (kg/cm²)3.69±0.15a3.87±0.12a4.05±0.09b*3.70±0.17a4.17±0.11b*0.041Eggshell thickness (mm)0.355±0.005a0.346±0.004a0.343±0.003a0.340±0.005 b*0.348±0.004a0.049Eggshell color (HG)54.18±1.0354.32±0.9952.91±0.8156.18±0.9454.18±0.590.142Albumen height (mm)5.86±0.185.37±0.165.55±0.255.68±0.215.72±0.270.572Haugh unit76.14±1.4472.29±1.4672.75±2.5974.26±1.9673.70±2.960.733Yolk color6.72±0.187.14±0.186.72±0.137.06±0.176.81±0.180.239Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group, ⁎⁎P < 0.01.⁎P < 0.05. Effects of PQQ supplementation on egg quality parameters of laying hens. Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group, ⁎⁎P < 0.01. P < 0.05. Effects of PQQ on serum biochemical parameters Serum biochemical parameters are presented in Table 6. Dietary PQQ supplementation decreased serum MDA concentrations at all doses compared with the control (P < 0.05 or P < 0.01). LDH activity was reduced in all PQQ groups (P < 0.05 or P < 0.01). CAT activity was elevated in all PQQ-supplemented groups, with significant increases at 1.0 mg/kg (P < 0.05) and 2.0 mg/kg groups (P < 0.01). SOD activity tended to increase but did not reach statistical significance (P > 0.05). T-AOC levels in the 0.5 and 1.0 mg/kg groups were higher than those in the control, but the differences were not statistically significant (P > 0.05).Table 6Effects of PQQ supplementation on serum biochemical parameters of laying hens.ParametersGroupsP-valuesControl0.5 mg/kg1.0 mg/kg2.0 mg/kg4.0mg/KgMDA (nmol/mL)8.12±0.75a6.39±0.28b*2.97±0.33c⁎⁎4.64±0.53d⁎⁎4.05±0.60cd*<0.001LDH (U/L)348.68±24.45a271.96±22.62b*237.67±11.10b⁎⁎267.01±28.24b*243.00±32.48b*0.024CAT (U/mL)8.96± 0.51a9.37±0.42ac10.20±0.42bc*10.75±0.42b⁎⁎9.90±0.32abc0.043SOD (U/L)14.37± 1.3815.86± 1.6017.79±1.0015.18± 1.5014.86± 1.190.437T-AOC (mM)0.26±0.040.30±0.030.30±0.030.27±0.060.26±0.030.865Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group.⁎P < 0.05,⁎⁎P < 0.01. Table 6Effects of PQQ supplementation on serum biochemical parameters of laying hens.ParametersGroupsP-valuesControl0.5 mg/kg1.0 mg/kg2.0 mg/kg4.0mg/KgMDA (nmol/mL)8.12±0.75a6.39±0.28b*2.97±0.33c⁎⁎4.64±0.53d⁎⁎4.05±0.60cd*<0.001LDH (U/L)348.68±24.45a271.96±22.62b*237.67±11.10b⁎⁎267.01±28.24b*243.00±32.48b*0.024CAT (U/mL)8.96± 0.51a9.37±0.42ac10.20±0.42bc*10.75±0.42b⁎⁎9.90±0.32abc0.043SOD (U/L)14.37± 1.3815.86± 1.6017.79±1.0015.18± 1.5014.86± 1.190.437T-AOC (mM)0.26±0.040.30±0.030.30±0.030.27±0.060.26±0.030.865Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group.⁎P < 0.05,⁎⁎P < 0.01. Effects of PQQ supplementation on serum biochemical parameters of laying hens. Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P < 0.05). Compared with the control group. P < 0.05, P < 0.01. Effects of PQQ on immune parameters The serum immune parameters of hens in each experimental group are presented in Fig. 1. Compared with the control group, serum IL-2 levels were slightly decreased in the 0.5 mg/kg and 1.0 mg/kg PQQ supplementation groups, although the differences were not statistically significant (P > 0.05). Dietary supplementation with different doses of PQQ significantly reduced serum IL-6 concentrations in laying hens (P < 0.01). Serum IL-10 levels were decreased in both the 0.5 mg/kg and 1.0 mg/kg PQQ supplementation groups, with a significant reduction observed in the 1.0 mg/kg group (P < 0.05). Compared with the control group, serum IFN-γ and TNF-α levels were reduced to varying degrees in PQQ-supplemented groups, but the differences did not reach statistical significance. Dietary PQQ supplementation had no significant effects on IgA or IgG levels in late-laying Jingfen No. 6 hens. However, intestinal mucosal sIgA content was increased in all PQQ-supplemented groups, with significant elevations observed in the 1.0 mg/kg and 4.0 mg/kg groups (P < 0.05).Fig. 1Effects of PQQ supplementation on immune parameters in laying hens. (A) Serum IL-2 concentrations. (B) Serum IL-6 concentrations. (C) Serum IL-10 concentrations. (D) Serum TFN-γ concentrations. (E) Serum TNF-α concentrations. (F-G) Serum IgG and IgA concentrations. (H) IgA concentrations in the intestine. *P < 0.05, **P < 0.01, compared with the control group. NS: no significance between the indicated groups. Effects of PQQ supplementation on immune parameters in laying hens. (A) Serum IL-2 concentrations. (B) Serum IL-6 concentrations. (C) Serum IL-10 concentrations. (D) Serum TFN-γ concentrations. (E) Serum TNF-α concentrations. (F-G) Serum IgG and IgA concentrations. (H) IgA concentrations in the intestine. *P < 0.05, **P < 0.01, compared with the control group. NS: no significance between the indicated groups. Effects of PQQ supplementation on intestinal health Effects of PQQ supplementation on intestinal morphology Based on the above findings, the 1.0 mg/kg PQQ supplementation group and the control group were selected for a comprehensive comparative analysis of intestinal health. Histological analysis of jejunal tissue sections revealed that, compared with the control group, hens receiving 1.0 mg/kg PQQ supplementation exhibited significantly increased villus height (P < 0.05), decreased crypt depth, and a significantly increased villus height-to-crypt depth ratio (P < 0.01) (Figs. 2A–D). Immunofluorescence analysis demonstrated that supplementation with 1.0 mg/kg PQQ markedly enhanced the staining intensity of the tight junction protein ZO-1 in jejunal tissue. Furthermore, quantitative real-time PCR analysis revealed that the mRNA expression levels of tight junction proteins in jejunal tissue were higher in the PQQ-supplemented group than in the control group, with significant increases observed for ZO-1 (P < 0.05) and Occludin (P < 0.01), while Claudin-1 exhibited an increase that did not reach statistical significance (P > 0.05) (Figs. 2E–H).Fig. 2Effects of PQQ supplementation on intestinal morphology in late-phase laying hens. (A) Histopathological examination of the jejunum (HE staining × 50). (B) The villi height of jejunum. (C) The crypt depth of jejunum. (D) Villi height to crypt depth ratio. (E) Sections of jejunum tissue were immunostained with anti-ZO-1 (red) and DAPI (blue) (50 × magnification). (F-H) The mRNA levels of ZO-1, Claudin-1, and Occludin in the jejunum. Values are presented as means ± standard errors of the means. *P < 0.05, **P < 0.01, compared with the control group. NS: no significance between the indicated groups. Effects of PQQ supplementation on intestinal morphology in late-phase laying hens. (A) Histopathological examination of the jejunum (HE staining × 50). (B) The villi height of jejunum. (C) The crypt depth of jejunum. (D) Villi height to crypt depth ratio. (E) Sections of jejunum tissue were immunostained with anti-ZO-1 (red) and DAPI (blue) (50 × magnification). (F-H) The mRNA levels of ZO-1, Claudin-1, and Occludin in the jejunum. Values are presented as means ± standard errors of the means. *P < 0.05, **P < 0.01, compared with the control group. NS: no significance between the indicated groups. Effects of PQQ supplementation on cecal microbiota composition The 16S high-throughput sequencing results of the intestinal microbiota of laying hens revealed that, compared with the control group, 1.0 mg/kg PQQ supplementation increased the α-diversity of the intestinal microbiota of laying hens, with significant differences in Shannon index and Simpson index (P < 0.05). β-diversity analysis revealed distinct clustering between the control group and the PQQ supplementation group, with significant differences in microbial diversity between groups (P < 0.05) (Fig. S1). The main phylum-level microbial species in the intestine of laying hens included Bacteroidetes, Firmicutes, Desulfobacterota, Spirochaetota, Proteobacteria, Deferribacteres, and Actinobacteria, with Bacteroidetes being the dominant phylum. Compared with the control group, the relative abundance of Bacteroidetes and Actinobacteria in the 1.0 mg/kg PQQ supplementation group was significantly decreased (P < 0.05), while the relative abundance of Firmicutes, Proteobacteria and Deferribacteres was significantly increased (P < 0.05) (Table 7). At the genus level, the relative abundance of Prevotellaceae_Ga6A1_group, Lactobacillus, Faecalibacterium, Clostridia_UCG-014, Paraprevotella, and Mucispirillum in the PQQ supplementation group was significantly increased compared with the control group, while the relative abundance of Rikenellaceae_RC9_gut_group, Shuttleworthia, and Alloprevotella was significantly decreased (Fig. 3). These results collectively indicated that dietary supplementation with 1 mg/kg PQQ could significantly affect the diversity and community structure of the intestinal microbiota of laying hens during the mid-to-late production cycle.Table 7Effects of PQQ supplementation on cecal microbiota composition at the phylum level in laying hens.PhylumGroupP-valuesControlPQQ groupBacteroidetes82.52 ± 0.87a78.34±1.03b*0.012Firmicutes10.80 ± 0.51a14.29±1.03b*0.013Desulfobacterota2.70 ± 0.242.96 ± 0.230.447Spirochaetota1.33±0.111.27±0.100.652Proteobacteria0.96 ± 0.06a1.23 ± 0.06b*0.011Deferribacterota0.24 ± 0.06a0.49 ± 0.07b*0.014Actinobacteria0.39 ± 0.02a0.26 ± 0.01b⁎⁎<0.001Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P <0.05). Compared with the control group.⁎P < 0.05,⁎⁎P < 0.01.Fig. 3Effects of PQQ supplementation on the abundance of cecal microbial genera in laying hens. (A) Heatmap of a cluster of gut microbes in each group. (B) Selected cecal bacterial genera with significant differences in relative abundance (Rikenellaceae_RC9_gut_group, Prevotellaceae_Ga6A1_group, Lactobacillus, Faecalibacterium, Clostridia_UCG-014, Shuttleworthia, Alloprevotella, Paraprevotella, and Mucispirillum). Values are presented as means ± standard errors of the means. *P < 0.05, **P < 0.01, compared with the control group. NS: no significance between the indicated groups. Table 7Effects of PQQ supplementation on cecal microbiota composition at the phylum level in laying hens.PhylumGroupP-valuesControlPQQ groupBacteroidetes82.52 ± 0.87a78.34±1.03b*0.012Firmicutes10.80 ± 0.51a14.29±1.03b*0.013Desulfobacterota2.70 ± 0.242.96 ± 0.230.447Spirochaetota1.33±0.111.27±0.100.652Proteobacteria0.96 ± 0.06a1.23 ± 0.06b*0.011Deferribacterota0.24 ± 0.06a0.49 ± 0.07b*0.014Actinobacteria0.39 ± 0.02a0.26 ± 0.01b⁎⁎<0.001Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P <0.05). Compared with the control group.⁎P < 0.05,⁎⁎P < 0.01. Effects of PQQ supplementation on cecal microbiota composition at the phylum level in laying hens. Note: Data are displayed as means ± SEs. Values within a row with different superscripts indicate significant differences among groups (P <0.05). Compared with the control group. P < 0.05, P < 0.01. Effects of PQQ supplementation on the abundance of cecal microbial genera in laying hens. (A) Heatmap of a cluster of gut microbes in each group. (B) Selected cecal bacterial genera with significant differences in relative abundance (Rikenellaceae_RC9_gut_group, Prevotellaceae_Ga6A1_group, Lactobacillus, Faecalibacterium, Clostridia_UCG-014, Shuttleworthia, Alloprevotella, Paraprevotella, and Mucispirillum). Values are presented as means ± standard errors of the means. *P < 0.05, **P < 0.01, compared with the control group. NS: no significance between the indicated groups. Effects of PQQ supplementation on the intestinal metabolome A total of 8,503 metabolic features were detected in the cecal contents, of which 4,128 metabolites were annotated with confidence levels. The annotated metabolites were classified into ten super classes (Fig. S2A), among which lipids and lipid-like molecules (36.09%), organic acids and derivatives (20.44%), organoheterocyclic compounds (14.74%), and benzenoids (9.08%) were the predominant categories. To assess the overall variation in metabolic profiles between groups, unsupervised principal component analysis (PCA) was performed. As shown in Fig. S2B, samples from the CON and PQQ groups formed two distinct clusters along PC1, indicating a clear separation of cecal metabolic profiles between the two groups and suggesting that dietary PQQ supplementation altered the cecal metabolic pattern of laying hens. Differential metabolites were subsequently identified using univariate statistical criteria (P < 0.05, combined with FC ≥ 4.0 or FC ≤ 0.25). Metabolomic profiling identified a total of 419 differential metabolites in the intestines of PQQ-treated hens relative to the control group. Among these, 89 metabolites were significantly upregulated, while 330 exhibited significant downregulation (Fig. 4A). Among all upregulated major metabolites, 23 were organic acid metabolites, including 6-(Pyridin-3-yl)hexanoic acid, DL-Valine-4-antipyrineamide, Eicosadienoic acid, 2-methyl-hexadecanoic acid, Penicilloic acid, etc.; 22 were lipids and lipid-like molecules, including 3-Methyl-3-butenyl tetradecanoate, Diglycerides (DG), Phosphatidylcholine (PC), etc. In addition, 13 upregulated organic heterocyclic compounds and 11 upregulated phenylpropanoids and polyketides were identified. Among all downregulated metabolites, 171 were related to lipid metabolism, including TG, PG, Monoglyceride (MG), (5alpha,17beta)-3-Oxoandrostan-17-yl undecanoate, etc (Fig. 4B). In addition, 39 downregulated organic heterocyclic compounds, 38 organic acid metabolites, and 25 benzene substances were identified. The differential metabolite data were annotated to only 12 pathways in the KEGG database, involving biological processes such as lipid metabolism, amino acid metabolism, carbohydrate metabolism, and cellular transport metabolism (Fig. S3).Fig. 4Principal component analysis and differential metabolite statistics of intestinal metabolites in laying hens. (A) Bar chart of differential intestinal metabolite statistics. (B) Major differential intestinal metabolites (Log2 fold change). Values are presented as means ± standard errors of the means. *P < 0.05, **P < 0.01, ***P < 0.001, compared with the control group. Principal component analysis and differential metabolite statistics of intestinal metabolites in laying hens. (A) Bar chart of differential intestinal metabolite statistics. (B) Major differential intestinal metabolites (Log2 fold change). Values are presented as means ± standard errors of the means. *P < 0.05, **P < 0.01, ***P < 0.001, compared with the control group. Correlation analysis between cecal microbiota and differential metabolites As shown in Fig. 5, the relative abundances of Prevotellaceae_Ga6A1_group, Lactobacillus, Mailhella, Faecalibacterium, Helicobacter, and Oscillospira were significantly increased in the PQQ group. These strains showed significant positive correlations with 6-(Pyridin-3-yl) hexanoic acid, Eicosadienoic acid, Dihydro-4-mercapto-3(2H)-furanone, and 1-Phenyl-1-cyclohexene, and significant negative correlations with TG, (5alpha,17beta)-3-Oxoandrostan-17-yl undecanoate, Cholylglutamic acid, etc. The abundances of Olsenella and Alloprevotella were significantly decreased in the PQQ group and showed significant negative correlations with major metabolites, including 6-(Pyridin-3-yl)hexanoic acid and Eicosadienoic acid (Fig. 5). The results indicated that PQQ supplementation significantly affected the levels of intestinal microbiota and major metabolites, which may be an important mechanism underlying its improvement in production performance and physical health status in laying hens.Fig. 5Correlation analysis between intestinal microbiota and top differential metabolites in laying hens. (A) Correlation heatmap. (B) Correlation network diagram. *P < 0.05, **P < 0.01, ***P < 0.001. "Unlabeled" indicates no correlation between changes in intestinal microbiota and metabolites. Correlation analysis between intestinal microbiota and top differential metabolites in laying hens. (A) Correlation heatmap. (B) Correlation network diagram. *P < 0.05, **P < 0.01, ***P < 0.001. "Unlabeled" indicates no correlation between changes in intestinal microbiota and metabolites. Discussion Pyrroloquinoline quinone functions as a growth-promoting nutrient that stimulates cell differentiation, thereby enhancing animal growth and production performance. Previous studies in broilers demonstrated that dietary supplementation with 0.2 mg/kg PQQ·Na₂ significantly improved growth performance and feed efficiency (Samuel et al., 2015; Wang et al., 2015). Similarly, Shao et al. (2023) reported that 0.4 mg/kg PQQ·Na₂ increased albumen height, Haugh units, and shell strength in 37-wk-old Hy-Line Brown hens. Consistent with these findings, the present study showed that 0.5 and 1.0 mg/kg PQQ increased average daily egg mass, laying rate, and feed conversion efficiency compared with the control. The improvements in egg production and feed conversion efficiency likely involve an interconnected network of enhanced intestinal function, microbiota remodeling, and coordinated metabolic shifts. The increased jejunal villus height and villus-to-crypt ratio expand the absorptive surface area, supporting efficient nutrient uptake for egg formation (Huang et al., 2024). Concurrently, upregulated ZO-1 and occludin strengthen the barrier, reducing metabolic costs of immune activation (Kuroda et al., 2026). The enrichment of Prevotellaceae_Ga6A1_group, Lactobacillus, and Faecalibacterium likely enhances fiber fermentation, and the metabolomic profile reveals a coordinated shift in which organic acid metabolites, including 6-(Pyridin-3-yl)hexanoic acid and eicosadienoic acid, were upregulated, whereas lipid metabolites, notably Triglycerides and Phospholipids, exhibited broad downregulation. The elevated organic acids may provide supplementary energy substrates for enterocytes and support barrier maintenance (Zeng et al., 2019), as supported by the positive correlations between Prevotellaceae_Ga6A1_group, Lactobacillus, and these acid metabolites in the correlation analysis, consistent with the notion that microbial metabolites mediate host-microbiome communication (Oke et al., 2025). Conversely, the reduction in specific lipid classes may reflect altered microbial processing of complex lipids in the cecum or modified host lipid absorption dynamics following PQQ-induced microbiota restructuring (Mohamad Ishak and Ikemoto, 2023). Collectively, these bidirectional metabolic adjustments, including enhanced fermentative output coupled with modified lipid metabolism, establish an intestinal environment favorable for nutrient absorption and reduced inflammatory burden, consistent with the observed decrease in serum IL-6 and improved productive performance. Additionally, mammalian studies have shown that PQQ exerts protective effects on female reproductive function, including improved ovarian reserve and restored estrous cyclicity (Dai et al., 2022; Liu et al., 2025; Zhang et al., 2019). Whether similar mechanisms contribute to the improved laying rate observed in the present study remains speculative, as reproductive organ parameters were not directly measured. Future work incorporating ovarian histology and hormone profiling in laying hens would help clarify this possibility. Egg quality parameters were differentially affected by PQQ supplementation. Haugh units were unchanged across all PQQ doses (0.5-4.0 mg/kg), whereas shell strength tended to increase. It is noteworthy that eggshell strength and thickness responded divergently to PQQ supplementation. The significant increase in shell strength at 1.0 and 4.0 mg/kg, concurrent with a slight thickness reduction, reflects the fact that breaking strength depends more on ultrastructural matrix organization—crystal orientation, mammillary cone density, and protein deposition—than on thickness per se (Fu et al., 2021; Yang et al., 2025). Egg quality is closely associated with energy metabolism and antioxidant status in the oviduct (Wang et al., 2015). PQQ-mediated enhancement of mitochondrial ATP production via SIRT1/PGC-1α activation may support the energy-intensive calcium transport process in the shell gland (Saihara et al., 2017; Wang et al., 2015; Yang et al., 2025), promoting efficient calcium deposition and matrix organization. Additionally, the observed reduction in MDA and elevation in CAT activity may protect uterine epithelial cells from oxidative damage, preserving secretory function and shell quality (Shao et al., 2023; Zhang et al., 2022). The observed effects on shell strength may be attributed to PQQ-mediated improvements in mitochondrial function and energy supply, though further investigation is warranted to elucidate these mechanisms. Oxidative stress represents a ubiquitous and inevitable challenge in animal production, and failure to mitigate it can adversely affect productive performance. Serum metabolites and enzyme activities serve as reliable indicators of oxidative status, with their concentrations reflecting the extent of peroxidation reactions. Pyrroloquinoline quinone and its derivatives function as potent electron transporters with superior free radical scavenging capacity compared with vitamin C, cysteine, and glutathione (Jonscher et al., 2021). Mechanistically, PQQ protects against oxidative stress by maintaining mitochondrial membrane stability and preventing respiratory chain protein carbonylation, thereby preserving enzymatic activity and attenuating lipid peroxidation (He et al., 2003). Consistent with previous reports in poultry (Qiu et al., 2021; Samuel et al., 2015; Wang et al., 2015; Zheng et al., 2020), the present study demonstrated that PQQ supplementation decreased serum MDA and LDH concentrations while increasing CAT activity across all doses, with variable effects on SOD. Shao et al. (2023) observed that 0.4 mg/kg PQQ·Na₂ elevated plasma glutathione peroxidase (GSH-Px) activity and reduced hepatic and yolk MDA concentrations in laying hens, accompanied by upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) expression. Similarly, PQQ protected against hepatocellular lipid accumulation through enhanced mitochondrial biogenesis and redox homeostasis (Qiu et al., 2021). In roosters, dietary PQQ·Na₂ at 1.0 mg/kg optimized serum, hepatic, renal, and testicular SOD and GSH-Px activities while reducing MDA, concurrently improving seminiferous tubule diameter and epithelial thickness (Long et al., 2022). Collectively, these findings indicate that PQQ mitigates oxidative damage and enhances antioxidant capacity in laying hens through free radical scavenging and upregulation of endogenous antioxidant enzymes. Immune competence is fundamental to maintaining health in laying hens, with antibody titers serving as critical indicators of resistance to pathogenic challenge. High-producing hens often experience negative nutrient balance, which can compromise immune function and alter serum antibody and cytokine profiles (Michael, 2022). The present study evaluated the effects of PQQ on responses to both the inactivated avian influenza vaccine (with adjuvant) and the live attenuated Newcastle disease vaccine. Previous investigations have demonstrated immunomodulatory effects of PQQ across species and experimental models. Dietary PQQ·Na₂ enhanced immune function in broilers in a dose-dependent manner, with 0.2 mg/kg stimulating immune organ development (Samuel et al., 2015). Similarly, 0.1 mg/kg PQQ·Na₂ elevated plasma lysozyme activity and promoted thymic development at 21 d and splenic development at 42 d, indicating that PQQ can enhance innate immune function in chickens (Samuel et al., 2015). A study reported that PQQ supplementation in mice increased T-cell responsiveness to mitogens and B-cell reactivity under lipopolysaccharide stimulation, concomitant with elevated serum IgM and IgG (Steinberg et al., 1994). Current evidence suggests that the immunomodulatory mechanisms of PQQ are multifaceted. Huang et al. (2020) reported that PQQ attenuated Escherichia coli toxin-induced intestinal damage through elevated secretory IgA, IL-10, and IL-22. In broilers challenged with LPS, 1.0 mg/kg PQQ·Na₂ significantly downregulated expression of pro-inflammatory cytokines IL-1β, IL-6, and IL-10, protecting against inflammatory injury and oxidative stress (Zheng et al., 2020). Besides, PQQ reduced pro-inflammatory gene expression and enhanced immune competence in mice fed high-fat diets (Jonscher et al., 2017). Consistent with these findings, the present study demonstrated that 0.5-1.0 mg/kg PQQ increased antibody titers against H5, H7, and Newcastle disease virus, decreased serum IL-6, and elevated intestinal sIgA. These effects may be mediated through established PQQ mechanisms, including Nrf2/ARE pathway activation, AMPK/PGC-1α-mediated mitochondrial biogenesis, and NF-κB inhibition (Wang et al., 2022). Furthermore, PQQ ameliorates cyclophosphamide-induced hepatic, renal, and splenic damage while suppressing inflammatory responses and organ toxicity (Lin et al., 2020; Qian et al., 2022). Collectively, these results suggest that PQQ modulates immune function through multiple pathways, thereby promoting health in aged laying hens. Intestinal integrity and the gut microbiota perform critical functions, including barrier protection, nutrient absorption, metabolic processing, immune regulation, and host defense. Dietary PQQ·Na₂ at 1 mg/kg attenuated LPS-induced reductions in duodenal villus height: crypt depth ratio in broilers (Zheng et al., 2020). Similarly, PQQ·Na₂ increased villus height in the duodenum and jejunum of weaned piglets and upregulated ZO-1 mRNA expression in neonatal piglets and both occludin and ZO-1 in weaned piglets (Wang et al., 2020). Consistent with these reports, the present study demonstrated that 1.0 mg/kg PQQ increased jejunal villus height and villus height: crypt depth ratio, concomitant with elevated mRNA expression of tight junction proteins ZO-1 and occludin. The jejunum serves as the primary site for digestion and nutrient absorption in poultry, with extensive villous structures and efficient epithelial cells facilitating uptake of amino acids, fatty acids, and monosaccharides (Shibata et al., 2023). Increased villus height expands absorptive surface area, thereby enhancing nutrient utilization efficiency. Tight junction proteins, including ZO-1, occludin, and claudin-1, constitute the physical barrier essential for maintaining intestinal integrity and epithelial homeostasis (Kpodo et al., 2024). These results indicate that 1.0 mg/kg PQQ improves intestinal structural integrity and absorptive capacity in aged laying hens. PQQ-induced improvements in intestinal morphology likely involve both direct protective effects and microbiota-mediated mechanisms. On the direct side, evidence from porcine models indicates that PQQ alleviates LPS-induced intestinal inflammation and epithelial apoptosis primarily through suppression of the MKK3/6-p38 signaling cascade, thereby preserving villus height and crypt architecture (Huang et al., 2024). Parallel in vitro and in vivo work in weaned pigs further demonstrates that PQQ upregulates Nrf2 and HO-1 expression in intestinal epithelial cells, reinforcing cellular antioxidant defenses against oxidative damage (Huang et al., 2021). Beyond these direct actions, the observed remodeling of gut microbiota likely contributes substantially to the morphological benefits. The enrichment of Lactobacillus and Faecalibacterium in PQQ-supplemented hens may enhance luminal short-chain fatty acid (SCFA) production, as supported by the positive correlations between these bacterial genera and organic acid metabolites in the present correlation analysis. SCFAs serve as the predominant oxidative fuel for colonocytes, supplying approximately 70% of their energy requirements via β-oxidation, and actively stimulate epithelial proliferation and tight junction assembly (Cowles, 2021; Zeng et al., 2019). Additionally, the reduction in systemic inflammatory tone, evidenced by decreased serum IL-6, likely alleviates immune-mediated epithelial injury and promotes villus recovery. Collectively, reduced inflammation, enhanced antioxidant capacity, and microbial metabolite support act in concert to improve intestinal integrity. Dietary PQQ modulates intestinal microbiota composition across species. Supplementation with 20 mg/kg PQQ to gestating and lactating sows increased Firmicutes and Alloprevotella abundance while decreasing Proteobacteria, Actinobacillus, and Escherichia in weaned piglets (Wang et al., 2020). In mice with western diet-induced dysbiosis, PQQ reversed reductions in Parabacteroides and Lactobacillus and attenuated Ruminococcus expansion, contributing to microbiota restoration (Friedman et al., 2018). The present study demonstrated that PQQ decreased the relative abundances of Bacteroidota and Actinobacteriota while increasing the relative abundances of Proteobacteria and Deferribacterota. Notably, beneficial taxa including Prevotellaceae_Ga6A1_group, Lactobacillus, and Faecalibacterium were significantly enriched (Sanders et al., 2019; Shah et al., 2024; Xu et al., 2024). Consistently, Shao et al. (2023) reported that 0.4 mg/kg PQQ·Na₂ increased the abundance of Firmicutes, Microbacterium, Erysipelatoclostridium, Mailhella, Lachnospiraceae_UCG-010, and Herbaspirillum, suggesting that microbiota modulation represents a mechanism underlying PQQ biological effects. The observed bacterial shifts in response to PQQ supplementation likely reflect a combination of direct antimicrobial effects, altered intestinal environmental conditions, and enhanced host immune responses. The enrichment of Prevotellaceae_Ga6A1_group, a prominent fiber-degrading taxon, suggests enhanced fermentation capacity and increased production of beneficial metabolites such as SCFAs, which may improve energy harvest from the diet and support intestinal epithelial health (Qiu et al., 2022; Rychlik, 2020). The significant increase in Lactobacillus abundance is particularly noteworthy, as members of this genus produce lactic acid and bacteriocins that inhibit pathogen colonization while promoting a favorable acidic luminal environment (Shah et al., 2024). Faecalibacterium, a major butyrate producer known for its anti-inflammatory properties, may help maintain intestinal immune homeostasis and strengthen the epithelial barrier (Sanders et al., 2019). These beneficial shifts collectively contribute to improved nutrient absorption, enhanced barrier function, and reduced inflammatory tone, providing a mechanistic link to the observed improvements in production performance. Regarding the Proteobacteria increase, this phylum encompasses both pathogens and functionally important commensals (Carrasco et al., 2019; Maki et al., 2019). Several observations suggest that this may not represent pathogenic colonization: the expansion coincided with Lactobacillus and Faecalibacterium enrichment, reduced serum IL-6, and increased intestinal sIgA. PQQ-mediated antioxidant enhancement may alleviate epithelial oxidative stress, thereby reducing the inflammatory signaling that typically selects for pathogenic Proteobacteria (Khan et al., 2020). Additionally, the elevated organic acid concentrations establish an acidic luminal environment that suppresses pH-sensitive pathogens while permitting acid-tolerant commensals to persist (Melaku et al., 2021). Collectively, these shifts fostered a metabolic milieu conducive to microbial fermentation and epithelial energy supply, consistent with the improved feed conversion and laying performance. While these findings support a commensal-dominant interpretation of the Proteobacteria expansion, the taxonomic resolution afforded by 16S rRNA amplicon sequencing remains inadequate for precise functional assignment at the genus or species level; more in-depth integrative sequencing analyses are warranted to elucidate the functional and metabolic potential of the specific taxa enriched in this study. Metabolomic analysis revealed that 1.0 mg/kg PQQ upregulated organic acids, including 6-(Pyridin-3-YL)hexanoic acid, DL-Valine-4-antipyrineamide, Eicosadienoic acid, 2-methyl-hexadecanoic acid and Penicilloic acid, while downregulating lipid metabolites such as TG, PG, and MG. Correlation analysis indicated positive associations between Prevotellaceae_Ga6A1_group, Lactobacillus, Faecalibacterium, and Helicobacter with 6-(Pyridin-3-yl)hexanoic acid, Eicosadienoic acid, and Dihydro-4-mercapto-3(2H)-furanone, whereas Olsenella and Alloprevotella showed negative correlations with key metabolites. The significant correlations observed between beneficial bacterial genera and organic acid metabolites suggest potential causal relationships. PQQ-mediated microbiota modulation correlates with improved hepatic health through the gut-liver axis (Friedman et al., 2018). Interestingly, Xu et al. (2025) reported that PQQ increased Lactobacillus and Bifidobacterium abundance and short-chain fatty acid production, concomitant with elevated tricarboxylic acid cycle intermediates (citrate, isocitrate, and malate), indicative of enhanced mitochondrial function. Based on established microbiome-metabolite interactions, we propose that the microbial alterations likely drive, at least in part, the observed metabolite changes. Prevotellaceae_Ga6A1_group, Lactobacillus, and Faecalibacterium are well-established producers of SCFAs and other organic acids through fermentation of dietary carbohydrates and fibers (Liu et al., 2022). The significant positive correlations between these genera and upregulated organic acids (including Eicosadienoic acid and 6-(Pyridin-3-yl)hexanoic acid) support the hypothesis that PQQ-induced enrichment of these taxa enhances their metabolic output, leading to increased luminal organic acid concentrations. However, the possibility of reverse causation or bidirectional interactions should also be considered. Certain metabolites present in the intestinal lumen may create a selective environment that favors the growth of specific bacterial taxa. For example, organic acids lower intestinal pH, which can suppress the growth of acid-sensitive pathogenic bacteria while promoting acid-tolerant beneficial species such as Lactobacillus (Feng et al., 2023). Additionally, PQQ itself may function as a signaling molecule that directly modulates microbial gene expression or community structure, independent of host-mediated effects (Ando et al., 2025). The recent discovery that PQQ can activate GPR35, a receptor for microbial metabolites, suggests potential cross-kingdom signaling mechanisms that warrant further investigation. This novel mechanism suggests PQQ may mimic or modulate microbial signaling pathways, warranting further investigation in poultry models. It should be acknowledged that the mechanistic analyses, including intestinal morphology, microbiome, and metabolomics, were conducted only in the 1.0 mg/kg PQQ group. This approach was selected because 1.0 mg/kg demonstrated the most consistent improvements in production performance and immune parameters. However, this limits our ability to establish dose-response relationships for intestinal and microbial parameters. Future studies should evaluate multiple PQQ doses using these omics approaches to fully characterize the dose-dependent effects on gut health and microbiota composition. Conclusion Our findings demonstrated that dietary PQQ at 0.5 and 1.0 mg/kg could significantly improve laying rate, average daily egg mass, and feed conversion ratio compared with the control. These performance benefits were accompanied by enhanced antioxidant capacity, as evidenced by reduced serum MDA and LDH, and elevated CAT activity. At 1.0 mg/kg, PQQ supplementation increased antibody titers against H5, H7, and NDV, decreased pro-inflammatory cytokine IL-6, and elevated intestinal sIgA. The mechanistic analyses conducted at 1.0 mg/kg revealed that PQQ promoted intestinal health through improved villus morphology, upregulated tight junction protein (ZO-1 and occludin) mRNA expression, and enrichment of beneficial microbiota including Prevotellaceae_Ga6A1_group, Lactobacillus, and Faecalibacterium, with metabolic profiles altered to increase organic acids and reduce certain lipid metabolites. While both 0.5 and 1.0 mg/kg PQQ improved production performance, the 1.0 mg/kg dose demonstrated more consistent benefits across immune, antioxidant, and intestinal parameters. Collectively, these findings demonstrate that PQQ enhances production performance, immune competence, and intestinal integrity in late-phase laying hens through integrated modulation of antioxidant status, inflammatory responses, gut morphology, microbiota composition, and metabolic function. Based on the comprehensive evaluation of all measured parameters, dietary supplementation of PQQ at 1.0 mg/kg represents the optimal dose for mitigating age-related decline in Jingfen No. 6 laying hens. Data availability Upon reasonable request, the datasets of this study can be available from the corresponding author. Author contributions K.Z. conceived and designed the study, secured the financial support, and takes overall responsibility for the integrity of the work. X.S. co-designed the experiment, performed the animal trial and laboratory analyses, analyzed the data, and drafted the manuscript. W.L. co-designed the experiment, supervised the animal trial, and substantively revised the manuscript. X.W. performed the animal feeding trial, collected the raw data and samples for part of the experiments, and contributed to data interpretation. R.Z. carried out the histopathological processing, immunohistochemistry, and morphometric analyses of the intestinal tissues, and interpreted the results. L.Y. performed the statistical and bioinformatic analyses of the intestinal microbiota and metabolome data, and determined egg quality. D.Y. conducted the serum biochemical, antioxidant, and immune analyses, and contributed to data interpretation. Y.D. participated in the determination of production performance and supervised the sample collection and laboratory analyses. H.H. contributed to the interpretation of the microbiota and metabolome data and critically revised the manuscript for important intellectual content. Y.L. participated in the study design and data interpretation, and critically revised the manuscript. J.W. analyzed the histological and production data, prepared the figures, and contributed to the writing of the Results section. X.H. and X.P. supervised the overall experimental work, contributed to the interpretation of the results, and critically revised the manuscript for important intellectual content. All authors discussed the results, read, and approved the final version of the manuscript. Disclosures We declare that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part. All authors listed have approved the manuscript that is enclosed. Authors report no conflict of interest.